North America Digital Diabetes Management Market size exceeded USD 4,150 million in 2020 and is estimated to observe a growth rate of 18.6% from 2021 to 2027.
Digital diabetes management includes technologies, platforms, devices, and services that helps patients in glucose monitoring, diet management, insulin management, and other health related parameters. This supports patients in capturing data, store or transmit data for clinical applications and diabetes management.
Get more details on this report - Request Free Sample PDF
Digital diabetes management products can address complexities in the current medication by providing enhanced access to information and improved self-management of diabetes. Continuous improvement in software-driven connected technologies, that can detect presence of disease or condition of interest are augmenting the North American digital diabetes management industry growth. Furthermore, other digital measures such as patient conditions, functioning and endurance are the factors that will influence the use of digital diabetes products.
Increasing access to digital diabetes products owing to favourable reimbursement, interoperability, marketing approval, and speedy FDA approval are the factors contributing to the market revenue. Continuous technological innovation in diabetes space is moving diabetes management towards seamless and remote chronic disease management.
North American Market, By Product Type
In devices segment, smart CGM devices accounted for more than USD 1.2 billion in 2020. Features including advanced connectivity with insulin delivery devices such as closed loop insulin pumps and smart insulin pens assist in driving the product demand. Moreover, advanced connectivity of CGM devices with various mobile applications and program dosing algorithms will also contribute to segment demand.
North American Market, By Patient Type
Type 1 diabetes segment is poised to witness over 17.9% CAGR through 2027. Increasing number of type 1 patients and rise in use of digital diabetes products are the factors contributing to the segment expansion. Type 1 diabetes patients require continuous monitoring and insulin infusion, thereby increasing the demand for digital products. Moreover, significant improvement in clinical outcome and cost-effectiveness of digital diabetes products have increased the segment growth.
North American Market, By End-use
Homecare setting segment is anticipated to expand at a CAGR of 18.9% till 2027. Increasing awareness about self-medication of diabetes and rising adoption of user-friendly diabetes devices will drive the segment growth. For instance, August 2017, the American Diabetes Association and WellDoc announced the launch of Diabetes Digital Health Learning Network to assist diabetes patients in achieving next-generation skill in using digital diabetes products.
North American Market, By Country
U.S. digital diabetes management market size was over USD 3 billion in 2020. Local presence of key players and large diabetes population base are boosting the demand for advanced diabetes monitoring devices. According to the International Diabetes Federation, there were more than 30.0 million people were living with diabetes in 2019 and this number is projected to reach 36.0 million by 2045. Furthermore, increasing adoption of smart devices and continuous adoption of novel technologies such as artificial intelligence and big data analytics are the factors impacting the market demand.
Competitive Market Share
Major players involved in North America market include Abbott Laboratories, Medtronic Plc, Insulet Corporation, F.Hoffmann-LA Roche Ltd., Dexcom, Inc., Companion Medical, Ypsomed, Tandem Diabetes, and Glooko, Inc, among several others. Thus, robust sales of digital diabetes products in the U.S. and continuous technological innovations in the field of digital diabetes are driving market expansion.